|
Publication Detail
-
Neuroscience and accelerator mass spectrometry
Publish date: Feb 01, 2005
Author: Magnus Palmblad, Bruce A. Buchholz, Darren J. Hillegonds and John S. Vogel
Source: J Mass Spectrom. 2005 Feb;40(2):154-9.
Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying rare isotopes. It has had a great impact in geochronology and archaeology and is now being applied in biomedicine. AMS measures radioisotopes such as 3H, 14C, 26Al, 36Cl and 41Ca, with zepto- or attomole sensitivity and high precision and throughput, allowing safe human pharmacokinetic studies involving microgram doses, agents having low bioavailability or toxicology studies where administered doses must be kept low (<1 microg kg(-1)). It is used to study long-term pharmacokinetics, to identify biomolecular interactions, to determine chronic and low-dose effects or molecular targets of neurotoxic substances, to quantify transport across the blood-brain barrier and to resolve molecular turnover rates in the human brain on the time-scale of decades. We review here how AMS is applied in neurotoxicology and neuroscience.
|
|
![[Logo]](/images/banner_home4.png "to Vitalea home page")
![[Pubmed entry]](/images/pubmed_icon.gif "Pubmed entry"){kind=icon}
![[neuroscience_and_AMS.pdf : Acrobat PDF document]](/images/acrobat_16.jpg "neuroscience_and_AMS.pdf : Acrobat PDF document"){kind=small}